Overview

Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy

Status:
Terminated

Trial end date:
2020-01-15

Target enrollment:

Participant gender:

Summary

This was an open-label, multicenter, prospective trial to assess safety and efficacy of 177Lu-PSMA-617 in patients with metastatic castration resistant prostate cancer.

Phase:

Phase 2

Details

Lead Sponsor:

Endocyte
Excel Diagnostics and Nuclear Oncology Center

Collaborator:

University of California, Los Angeles

Treatments:

177Lu-PSMA-617